Region-specific association of subjective cognitive decline with tauopathy independent of global β-amyloid burden

JAMA Neurology

Volumn 74, Issue 12, 2017, Pages 1455-1463

  Buckley, Rachel F ^a,b,c,d   Hanseeuw, Bernard ^c,d,e   Schultz, Aaron P ^c   Vannini, Patrizia ^c,d   Aghjayan, Sarah L ^c   Properzi, Michael J ^c   Jackson, Jonathan D ^c,d   Mormino, Elizabeth C ^c,d   Rentz, Dorene M ^c,d   Sperling, Reisa A ^c,d   Johnson, Keith A ^c,d   Amariglio, Rebecca E ^c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; FLORTAUCIPIR F 18; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; DIETHYL-1,3,6,8-TETRAHYDRO-1,3,6,8-TETRAOXOBENZO(LMN)(3,8)PHENANTHROLINE-2,7-DIACETATE; PHENANTHROLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE BURDEN; ENTORHINAL CORTEX; FEMALE; HUMAN; INFERIOR TEMPORAL CORTEX; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; TAUOPATHY; BRAIN; DIAGNOSTIC IMAGING; FRONTAL LOBE; METABOLISM; MIDDLE AGED; NEOCORTEX; PARIETAL LOBE; SELF EVALUATION; TEMPORAL LOBE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BRAIN; CARBOLINES; COGNITIVE DYSFUNCTION; CROSS-SECTIONAL STUDIES; DIAGNOSTIC SELF EVALUATION; ENTORHINAL CORTEX; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; NEOCORTEX; PARIETAL LOBE; PHENANTHROLINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SURVEYS AND QUESTIONNAIRES; TAU PROTEINS; TAUOPATHIES; TEMPORAL LOBE;

EID: 85039055013     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2017.2216     Document Type: Article

References (52)

1. Luck T, Luppa M, Matschinger H, Jessen F, Angermeyer MC, Riedel-Heller SG. Incident subjective memory complaints and the risk of subsequent dementia. Acta Psychiatr Scand. 2015;131(4):290-296.
2. Buckley RF, Maruff P, Ames D, et al; AIBL Study. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimers Dement. 2016;12(7):796-804.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
4. Wolfsgruber S, Jessen F, Koppara A, et al. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. Neurology. 2015;84(12):1261-1268.
5. Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50(12):2880-2886.
6. Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006;27(12):1751-1756.
7. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001;22(5):747-754.
8. Scheef L, Spottke A, Daerr M, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology. 2012;79(13):1332-1339.
9. Kryscio RJ, Abner EL, Cooper GE, et al. Self-reported memory complaints: implications from a longitudinal cohort with autopsies. Neurology. 2014;83(15):1359-1365.
10. Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology. 2006;67(9):1581-1585.
11. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119.
12. Schöll M, Lockhart SN, Schonhaut DR, et al. PET imagingoftau deposition inthe aging human brain. Neuron. 2016;89(5):971-982.
13. MarquiéM, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787-800.
14. Hanseeuw BJ, Betensky RA, Schultz AN, et al. FDG metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017;81(4):583-596.
15. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381.
16. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
17. Thal DR, Rüb U, Orantes M, Braak H. Phasesof A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-1800.
18. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
19. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48(8):314-318.
20. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983-1983;17(1):37-49.
21. Wechsler D. Wechsler Memory Scale-Revised. San Antonio, TX: Psychological Corp; 1987.
22. Gilewski MJ, Zelinski EM, Schaie KW. The Memory Functioning Questionnaire for assessment of memory complaints inadulthood and old age. Psychol Aging. 1990;5(4):482-490.
23. Farias ST, Mungas D, Reed BR, et al. The measurement ofEveryday Cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22(4):531-544.
24. Amariglio RE, Townsend MK, Grodstein F, Sperling RA, Rentz DM. Specific subjective memory complaints in older persons may indicate poor cognitive function. J Am Geriatr Soc. 2011;59(9):1612-1617.
25. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63(2):178-188.
26. Shoup TM, Yokell DL, Rice PA, et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm. 2013;56(14):736-740.
27. Becker JA, Hedden T, Carmasin J, et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032-1042.
28. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904-911.
29. Labbé C, Koepp M, Ashburner J, et al. Absolute PET quantification with correction for partial volume effects within cerebral structures. In: Quantitative FBIWPET, ed. Carson RE, DaubeWitherspoon ME, Herscovitch, P. Bethesda, MD: National Institutes of Health; 1998:59-66.
30. Greve DN, Salat DH, Bowen SL, et al. Different partial volume correction methods lead to different conclusions: an (18) F-FDG-PET study of aging. Neuroimage. 2016;132:334-343.
31. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. JCereb Blood Flow Metab. 2005;25(11):1528-1547.
32. Mormino EC, Betensky RA, Hedden T, et al; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study. Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767.
33. Li Q, Racine J. Cross-validated local linear nonparametric regression. Stat Sin. 2004;14:485-512.
34. Lindeman RH, Merenda PF, Gold RZ. Introduction to Bivariate and Multivariate Analysis. London, England: Scott Foresman; 1980.
35. Dormann CF, Elith J, Bacher S, et al. Collinearity: a review of methods to deal with it and a simulation study evaluating their performance. Ecography. 2013;36(1):27-46.
36. Hill NL, Mogle J, Wion R, et al. Subjective cognitive impairment and affective symptoms: a systematic review. Gerontologist. 2016;56(6):e109-e127.
37. Beach TG, Sue LI, Walker DG, et al. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. J Alzheimers Dis. 2012;28(4):869-876.
38. Amariglio RE, Mormino E, Vannini P, et al. Greater subjective cognitive concerns correspond with advancing stages of preclinical AD. Alzheimers Dement. 2014;10(4):566.
39. Colijn MA, Grossberg GT. Amyloid and tau biomarkers in subjective cognitive impairment. J Alzheimers Dis. 2015;47(1):1-8.
40. Duyckaerts C, Braak H, Brion J-P, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129(5):749-756.
41. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology. 1999;52(6):1158-1165.
42. Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(pt 5):1551-1567.
43. Braak H, Thal D R M D, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960-969.
44. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): acommon pathology associated with human aging. Acta Neuropathol. 2014;128(6):755-766.
45. Pontecorvo M, Devous M, Joshi A, et al. Relationships between 18F-AV-1451 (aka 18F-T807) PET tau binding and amyloid burden in cognitively normal subjects and patients with cognitive impairments suspected of Alzheimer's disease. J Nucl Med. 2015;56(suppl 3):245.
46. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(pt 7):2020-2033.
47. Sanders DW, Kaufman SK, De Vos SL, etal. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271-1288.
48. Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron. 2014;82(4):756-771.
49. Villemagne VL, Okamura N. Tau imagingin the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. Curr Opin Neurobiol. 2016;36:43-51.
50. Beharry C, Cohen LS, Di J, Ibrahim K, Briffa-Mirabella S, Alonso AdC. Tau-induced neurodegeneration: mechanisms and targets. Neurosci Bull. 2014;30(2):346-358.
51. Jessen F, Amariglio RE, van Boxtel M, et al; Subjective Cognitive Decline Initiative (SCD-I) Working Group. Aconceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10(6):844-852.
52. Molinuevo JL, Rabin LA, Amariglio R, et al; Subjective Cognitive Decline Initiative (SCD-I) Working Group. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017;13(3):296-311.